دورية أكاديمية
Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.
| العنوان: | Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients. |
|---|---|
| المؤلفون: | Aoude LG; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia. l.aoude@uq.edu.au., Wong BZY; Princess Alexandra Hospital, Department of Medical Imaging, Woolloongabba, Queensland, Australia.; Department of Medical Imaging, Gold Coast University Hospital, Southport, Australia., Bonazzi VF; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia., Brosda S; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia., Walters SB; School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland, Australia., Koufariotis LT; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Naeini MM; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Pearson JV; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Oey H; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia., Patel K; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia., Bradford JJ; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia., Bloxham CJ; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia., Atkinson V; Queensland Melanoma Project, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.; Faculty of Medicine, University of Queensland, St Lucia, Queensland, Australia., Law P; Princess Alexandra Hospital, Department of Medical Imaging, Woolloongabba, Queensland, Australia., Strutton G; Department of Anatomical Pathology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Bayley G; Queensland Melanoma Project, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Yang S; Queensland Melanoma Project, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Smithers BM; Queensland Melanoma Project, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.; Faculty of Medicine, University of Queensland, St Lucia, Queensland, Australia., Waddell N; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Miles K; Princess Alexandra Hospital, Department of Medical Imaging, Woolloongabba, Queensland, Australia., Barbour AP; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia.; Queensland Melanoma Project, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. |
| المصدر: | Molecular cancer research : MCR [Mol Cancer Res] 2021 Jun; Vol. 19 (6), pp. 950-956. Date of Electronic Publication: 2021 Apr 02. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101150042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3125 (Electronic) Linking ISSN: 15417786 NLM ISO Abbreviation: Mol Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research, c2002- |
| مواضيع طبية MeSH: | Biomarkers, Tumor/*genetics , CD8-Positive T-Lymphocytes/*metabolism , Melanoma/*diagnostic imaging , Positron Emission Tomography Computed Tomography/*methods , Skin Neoplasms/*diagnostic imaging, Humans ; Immunotherapy/methods ; Kaplan-Meier Estimate ; Melanoma/genetics ; Melanoma/therapy ; Mutation ; Prognosis ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/metabolism ; Proto-Oncogene Proteins p21(ras)/genetics ; Proto-Oncogene Proteins p21(ras)/metabolism ; RNA-Seq/methods ; Skin Neoplasms/genetics ; Skin Neoplasms/therapy ; Tumor Microenvironment/genetics ; Exome Sequencing/methods |
| مستخلص: | Treatment for metastatic melanoma includes targeted and/or immunotherapy. Although many patients respond, only a subset has complete response. As late-stage patients often have multiple tumors in difficult access sites, non-invasive techniques are necessary for the development of predictive/prognostic biomarkers. PET/CT scans from 52 patients with stage III/IV melanoma were assessed and CT image parameters were evaluated as prognostic biomarkers. Analysis indicated patients with high standard deviation or high mean of positive pixels (MPP) had worse progression-free survival ( P = 0.00047 and P = 0.0014, respectively) and worse overall survival ( P = 0.0223 and P = 0.0465, respectively). Whole-exome sequencing showed high MPP was associated with BRAF mutation status ( P = 0.0389). RNA-sequencing indicated patients with immune "cold" signatures had worse survival, which was associated with CT biomarker, MPP4 ( P = 0.0284). Multiplex immunofluorescence confirmed a correlation between CD8 expression and image biomarkers ( P = 0.0028). IMPLICATIONS: CT parameters have the potential to be cost-effective biomarkers of survival in melanoma, and reflect the tumor immune-microenvironment. VISUAL OVERVIEW: http://mcr.aacrjournals.org/content/molcanres/19/6/950/F1.large.jpg. (©2021 American Association for Cancer Research.) |
| References: | Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–57. Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24:1260–70. Massi D, Rulli E, Cossa M, Valeri B, Rodolfo M, Merelli B, et al. The density and spatial tissue distribution of CD8(+) and CD163(+) immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. J Immunother Cancer. 2019;7:308. Galon J, Bruni D. Approaches to treat immune hot, altered, and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218. Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the T-cell–inflamed versus non-t cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19–31. Schroer-Gunther MA, Wolff RF, Westwood ME, Scheibler FJ, Schurmann C, Baumert BG, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev. 2012;1:62. Miles KA, Ganeshan B, Rodriguez-Justo M, Goh VJ, Ziauddin Z, Engledow A, et al. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. J Nucl Med. 2014;55:386–91. Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti–PD-1 or anti–PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19:1180–91. Smith AD, Gray MR, del Campo SM, Shlapak D, Ganeshan B, Zhang X, et al. Predicting overall survival in patients with metastatic melanoma on antiangiogenic therapy and RECIST stable disease on initial posttherapy images using CT texture analysis. AJR Am J Roentgenol. 2015;205:W283–93. Miles KA, Ganeshan B, Hayball MP. CT texture analysis using the filtration-histogram method: what do the measurements mean?. Cancer Imaging. 2013;13:400–6. Aoude LG, Bonazzi VF, Brosda S, Patel K, Koufariotis LT, Oey H, et al. Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports. 2020;10:17687. Song S, Nones K, Miller D, Harliwong I, Kassahn KS, Pinese M, et al. A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS ONE. 2012;7:e45835. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. DeLuca DS, Levin JZ, Sivachenko A, Fennell T, Nazaire MD, Williams C, et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics. 2012;28:1530–2. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity.. 2019;51:411–2. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175–80. Katsoulakis E, Yu Y, Apte AP, Leeman JE, Katabi N, Morris L, et al. Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. Oral Oncol. 2020;110:104877. Tangella LP, Clark ME, Gray ES. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma—a mini review. Biochim Biophys Acta Gen Subj. 2020;1865:129736. Attrill GH, Ferguson PM, Palendira U, Long GV, Wilmott JS, Scolyer RA. The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell Melanoma Res. 2021;34:529–49. Kennedy LB, Salama AKS. A review of immune-mediated adverse events in melanoma. Oncol Ther. 2019;7:101–20. Meirson T, Asher N, Bomze D, Markel G. Safety of BRAF+MEK inhibitor combinations: severe adverse event evaluation. Cancers. 2020;12:1650. |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) |
| تواريخ الأحداث: | Date Created: 20210403 Date Completed: 20220124 Latest Revision: 20221207 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1158/1541-7786.MCR-20-1038 |
| PMID: | 33811161 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-3125 |
|---|---|
| DOI: | 10.1158/1541-7786.MCR-20-1038 |